Our partner, KLEER CBD Water, just launched their line of CBD-infused sparkling water, powered by SōRSE!
Learn more about cannabis beverages and how they have finally taken off in this article in Rolling Stone, featuring SōRSE and our partner, Cann.
Through our partnership with The Valens Company and A1 Cannabis, our technology powered the first cannabis beverage to market in Canada!
“These products were developed using the SōRSE by Valens emulsion technology which transforms cannabis oil into water-soluble extracts while eliminating cannabis taste, colour, or smell. These beverages have a fast onset time, significantly reduce offset time, increased bioavailability of cannabinoids, and are stable enough to achieve more than a one-year shelf life.”
Check out the full overview of the current beverage market in Canada from ADCANN.
Edibles are already a staple of many people’s cannabis lineup, and lately, due to the pandemic, some may even be choosing to forgo smoking entirely and switch to edibles due to health concerns.
Read about our CSO, Scott Riefler’s insights on edibles and its shelf life in Leafly’s article.
SōRSE is proud to be a part of such an incredible collaboration with The Valens Company and A1 Cannabis. Read about the two new beverages powered by SōRSE in the Canadian 2.0 Cannabis Market.
The March publication of the International Financial Law Review (IFLR) featured a piece entitled, Covid 19: Merger & Acquisitions market stalls amid uncertainty. SōRSE CEO Howard Lee offered his thoughts on company acquisitions during this crisis, including comments on our acquisition of Pascal Biosciences.
Check out SōRSE’s feature in Cultivated, Business Insider’s weekly newsletter where you get an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom. Cultivated highlights SōRSE acquisition of Pascal.
SōRSE CEO Howard Lee joined TheStreet to discuss what SōRSE brings to the cannabis industry and how our new partnership with Pascal could be a game changer for the industry.
VANCOUVER, British Columbia, & SEATTLE, Wash.– Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal”) has entered into a Term Sheet with SōRSE Technology (“SōRSE”) to develop Pascal’s cannabinoid programs. Investing in and financially supporting Pascal Biosciences’ research marks the first step for SōRSE Technology moving into medical research applications. This partnership leverages SōRSE’s industry-leading formulation technology with Pascal’s cannabinoid programs for clinical trials, led by Patrick Gray and his team of world-class medical researchers.
SōRSE Technology sells and licenses a proprietary water-soluble cannabinoid emulsion technology (patent-pending) that enables increased bioavailability, accurate dosing, and over 12 months shelf stability. SōRSE Technology is science and data-driven, with 53 employees, 30 of whom specialize in R&D and Quality Assurance. SōRSE currently has multiple partnerships which provide a profitable revenue stream.
SōRSE technology will enable other cannabinoid researchers to build a network of doctors and scientists that can lead the world in offering cannabinoid health solutions. Pascal is the first company to identify a mechanism for cannabinoids to directly benefit cancer immunotherapy and is also developing a cannabinoid-derived drug targeting glioblastoma.
Pascal Biosciences is actively evaluating cannabinoid application research studies for potential participation. As a reputable cannabinoid industry leader, SōRSE Technology will partake in Pascal approved studies for the advancement of the industry and pharmaceutical applications.
“The potential of Pascal’s cannabinoid programs for clinical applications in combination with SōRSE’s proprietary emulsification methods offers a promising path for future medical applications of cannabinoid products,” said Dr. Patrick Gray, CEO of Pascal Biosciences. “This agreement comes on the heels of recent, successful collaborative efforts with SōRSE that allowed us to examine SōRSE formulations in several Pascal ongoing studies. The combination of SōRSE’s industry-leading technology with Pascal’s long-term biotech potential make this a meaningful transaction for our shareholders.”
“At SōRSE, we’re driven by our mission to help people better their lives through superior cannabinoid ingredients and delivery methods,” said SōRSE CEO Howard Lee. “We are excited to continue to support pharmaceutical studies of cannabinoids with the world-class researchers of Pascal Biosciences.”
About Pascal Biosciences Inc.
Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma; and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. Pascal will continue to work on this program, focusing on monoclonal antibodies for Acute Lymphoblastic Leukemia.
For more information, visit www.pascalbiosciences.com.
About SōRSE Technology
SōRSE Technology is a water-soluble emulsion technology designed for product developers to provide consumers with a better cannabis experience with greater bioavailability, near-perfect dosing, shelf-stability, and safe ingredients. Their patent-pending technology converts oil into SōRSE, a proprietary water-soluble emulsion, for seamless integration as an ingredient in food items, beverages, topicals, and medical applications.
SōRSE Technology currently powers more than 30 market-leading products in the cannabis, hemp and CBD industry. SōRSE‘s expertise allows for 360 degree solutions for product developers with minimal disruption to existing production procedures and methods. From sourcing ingredients to product formulation, the SōRSE team provides its partners unprecedented product safety and quality while optimizing compound bioavailability. Partnership opportunities include licensing, white labeling, product development, and cannabinoid research studies. SōRSE Technology is currently available in North America, South America, Europe, and Australia.
Julie Rathbun for Pascal Biosciences
Richard Laermer for SōRSE Technology
Tel: 212-741-5106 X 216